Revisión

Central nervous system infection by Bacillus cereus: a case report and literature review

M. Rollán-Martínez Herrera, P. González-Urdiales, A. Zubizarreta-Zamalloa, E. Rodríguez-Merino, F. Martínez-Dubarbie [REV NEUROL 2022;75:239-245] PMID: 36218254 DOI: https://doi.org/10.33588/rn.7508.2021412 OPEN ACCESS
Volumen 75 | Number 08 | Nº of views of the article 11.183 | Nº of PDF downloads 110 | Article publication date 16/10/2022
Icono-PDF-OFF Download PDF Castellano Icono-PDF-OFF Download PDF English Citation Search in PubMed
Share in: Facebook Twitter
Go to another issue
ABSTRACT Artículo en español English version
INTRODUCTION Bacillus cereus is a ubiquitous pathogen that usually produces self-limiting gastrointestinal symptoms. However, in susceptible patients, it can lead to central nervous system infections which are potentially fatal. DEVELOPMENT. We present the case of a 10-year-old male under chemotherapy treatment for acute lymphoblastic leukemia. During the induction period he developed a brain abscess due to B. cereus which was diagnosed through imaging tests and direct detection in the cerebrospinal fluid. His evolution was favorable with antibiotic treatment.

CONCLUSIONS So far, 26 other cases of central nervous system infections due to B. cereus have been described in literature, and besides being infrequent, they are a diagnostic challenge. However, in preterm infants, patients with hematological malignancies or central nervous system surgery, early suspicion should be established to start an appropriate antibiotic treatment and improve prognosis.
KeywordsAbscessBacillus cereusCarbapenemsCentral nervous systemCritical CareHematologic neoplasms CategoriesInfecciones
FULL TEXT Artículo en español English version

Introduction


Bacillus cereus is an aerobic or facultatively anaerobic, motile, and spore-forming gram-positive rod. It belongs to the Bacillus genus, along with Bacillus anthracis, Bacillus thuringiensis, Bacillus toyonensis, Bacillus mycoides, Bacillus pseudomycoides y Bacillus weihenstephanensis [1]. It is widely distributed in the environment and can be found in soil, air, fomites, and fresh and salt water. Typically, it produces mild, self-limited emetic and diarrheal syndromes after consuming food contaminated with the bacteria or its toxins. In immunocompetent people it does not usually cause serious diseases and if isolated in blood samples, it is often considered as a saprophytic contaminant [2]. However, in certain patients, such as neonates, immunosuppressed patients, and central line carriers, it can produce bacteriemia and other systemic infections including pneumonia or endocarditis. Central nervous system (CNS) infections due to B. cereus are uncommon but potentially fatal.
 

Development


Case report


We report the case of a 10-year-old male diagnosed with a high-risk early T-cell precursor acute lymphoblastic leukemia, which was treated according to LAL SEHOP-PETHEMA 2013 protocol. Two years after the diagnosis he developed an early CNS relapse and, hence he was treated according to the InteReALL HR 2010 with bortezomib protocol. During induction, after being neutropenic for four weeks (20 neutrophils/µL) he was receiving prophylaxis with cefepime, cotrimoxazole and fluconazole. In addition, he was being treated with acyclovir for herpes simplex virus type 1 skin infection. In that context, he developed an intense holocranial headache that did not respond to common analgesics. A cranial computed tomography scan showed a hypodense lesion in the right temporal lobe. Considering the possibility of an infectious origin, a lumbar puncture was performed and cefepime was replaced by meropenem and vancomycin.

Despite remaining afebrile, the first day after the clinic onset, he developed septic shock signs, so he was transferred to the pediatric intensive care unit for inotropic and vasoactive support. Antimicrobial spectrum was broadened with gentamycin and caspofungin.

Blood analysis showed a progressive increase of C reactive protein and procalcitonin (up to 312 mg/L and 47.58 ng/mL, respectively, on the third day of evolution) with no other biochemical alterations. Hematological analysis showed pancytopenia due to chemotherapy. Microbiological blood tests ruled out bacteremia and fungemia. All herpes viruses were negative. Urine and stool cultures were also negative. Biochemical analysis of the cerebrospinal fluid was strictly normal (glucose, 63 mg/dL; proteins, 16 mg/dL; leucocytes, 1/µL) but B. cereus was detected in microbiologic study (sensitive to meropenem, vancomycin, linezolid, and ciprofloxacin). Herpes simplex virus 1 and 2, herpes virus 6, cytomegalovirus, varicella-zoster virus, enterovirus, parechovirus, toxoplasma, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pneumoniae and Cryptococcus were ruled out in cerebrospinal fluid.

The electroencephalogram showed a diffuse slowing of brain activity with no epileptiform activity. After removing hemodynamic support, on the fourth day, a cranial magnetic resonance was performed. It showed two hyperintense lesions in T2 and FLAIR sequences affecting the subcortical region of the right temporal lobe and right parietal lobe. Parietal lesion presented ring-enhancing after gadolinium administration (Figure), and both lesions showed peripheral diffusion restriction. In addition, small hemorrhagic foci dispersed throughout the parenchyma were observed. The image suggested a bacterial origin by atypical germ, so these findings along with those in the cerebrospinal fluid, led to the diagnosis of B. cereus abscess.

 

Figure. a-c) Axial FLAIR showing a hyperintense cortical-subcortical lesion in right post-central region; d-f) Axial T1-weighted. The lesion shows a ring-enhancing after gadolinium administration.






 

After two weeks of treatment, the patient evol­ved favorably with no headache or findings on neurological examination. A control magnetic resonance showed a decrease in the size of the lesion. Vancomycin and acyclovir were suspended after three weeks and meropenem was maintained over six weeks.

Review methods


A literature review of B. cereus CNS infection was performed using the PubMed database. Cases in English, reported from 1990 to September 2020 under the terms ‘Bacillus cereus + Brain’, ‘Bacillus cereus + Cerebral’, ‘Bacillus cereus + Central nervous’ were selected. 21 relevant articles were identified and data of 26 cases were available for review.
 

Results


Between 1990 and 2020, 26 cases of patients with CNS infection by B. cereus have been indexed in PubMed [3-22] (Table). When analysing the age of patients, we have considered that each age throughout life has its own characteristics, so we have separated patients into three age groups: premature infants (n = 6), children-adolescents between 1-18 years (n = 5), and adults (n = 15). The mean age among children was 10.2 years (95% confidence interval: 6.61-13.78) and among adults was 52.9 years (95% confidence interval: 46.16-59.58). In preterm infants, the average gestational age was 31.33 weeks (95% confidence interval: 28.2-34.5). There was no statistically significant sex difference (47.8%, women; p = 0.11).

 

Table. Patients with CNS infections due to Bacillus cereus.
 
Age/Sex

Underlying situation

Sample

Clinical picture

Outcome

Treatment

Image

LP

Koizumi et al, 2020

54/F

AML

(neutropenia)

Blood + CSF

Headache, altered consciousness, meningeal signs, fever

Alive

MEPM, VCM, LZD

Meningeal inflammation, abscesses

+

Brouland et al, 2018

64/M

AML

(neutropenia)

Blood

Headache, coma, fever

Dead

MEPM, VCM, AMK

Lenticulostriatal bleed, cortico-subcortical occipital hypodensity.



Saigal et al, 2016

51/M

High-grade glioma

(CNS access)

Tumor biopsy

Headache, altered consciousness, seizures, fever

Alive

PIPC

Abscess



Melmed et al, 2016

34/F

ALL

(neutropenia)

Autopsy

Altered consciousness

Dead

N

Multiple abscesses



Vodopivec et al, 2015

32/F

AML

(neutropenia)

Biopsy

Headache, visual disturbances, fever

Alive

VCM

Abscess



Vodopivec et al, 2015

58/F

AML

(neutropenia)

Autopsy

Altered consciousness, seizures, fever

Dead

VCM

Subarachnoid hemorrhage, intraparenchymal hemorrhage, abscess



Vodopivec et al, 2015

54/F

AML

(neutropenia)

Autopsy

Altered consciousness, seizures, fever

Dead

DPM, VCM, LFX

Meningeal inflammation, abscess, infarcts (watershed)

+

Vodopivec et al, 2015

50/F

AML

(neutropenia)

Autopsy

Headache, visual disturbances, meningeal signs, fever

Dead

VCM

Diffuse brain edema, tonsillar herniation



Vodopivec et al, 2015

52/M

AML

(neutropenia)

Autopsy

Altered consciousness, fever

Dead

VCM

Subarachnoid hemorrhage, intraparenchymal hemorrhagic foci, diffuse brain edema



Dabscheck et al, 2015

5/M

ALL

(neutropenia)

Blood

Fever

Alive

MEPM

Abscess



Hansford et al, 2014

8/M

ALL

(neutropenia)

Blood

Headache, altered consciousness, fever

Alive

MEPM, CPFX, VCM

Multiple abscesses



Stevens et al, 2012

73/F

AML

(CNS access)

CSF

Headache, altered consciousness, meningeal signs, fever

Alive

VCM, CFP

N

+

Drazin et al, 2010

32 w/F

Prematurity

Blood

Altered consciousness

Alive with sequels

VCM, GM, MEPM, drainage

Multiple abscesses

+

Ichikawa et al, 2010

11/M

No

Stool

Seizures, fever

Alive

Methylprednisolone

Hyperintense lesions (cortex and watershed)

+

Manickam et al, 2008

34 w/M

Prematurity

Autopsy

Seizures

Dead

AMP, GM, VCM

Abscesses

+

Kuwabara et al, 2006

54/F

AML

(neutropenia)

Blood

Coma, fever

Alive

VCM, MEPM

Multiple abscesses



Lequin et al, 2005

30 w/N

Prematurity

Blood + CSF

Seizures, fever

Dead

N

Intraparenchymal

hemorrhagic foci

+

Lequin et al, 2005

28 w/N

Prematurity

Blood + CSF

Fever

Dead

N

Multiple abscesses

+

 

Patients reviewed presented three major predisposing factors. The most frequent was neutropenia (65.4%), followed by prematurity (23.1%) and CNS surgery (11.5%). Previous history of neurosurgical intervention was only present in the group of adults (2 patients). 72% of patients had a central line (all of them were neutropenic patients) and there was only one patient without a clear predisposing factor.

Almost all neutropenic patients (94,1%) presented some underlying haematological disease. Overall, the most frequent was acute myeloid leukaemia (58.8%), followed by acute lymphoblastic leukaemia (23.5%). Myelodysplastic syndrome and aplastic anaemia with bone marrow transplant were found in one patient each. By age groups, the most frequent malignancy among adults was acute myeloid leukaemia (76.9%) while in the group of children and adolescents it was acute lymphoblastic leukaemia (50%).

Manifestations of B. cereus in the CNS are varied. Abscesses were the most frequent finding (68%), specifically, multiple abscesses (44%). Haemorrhagic lesions were also frequent, both intraparenchymal haemorrhages (16%) and subarachnoid haemorrhages (8%). 19.2% of patients showed inflammatory lesions or diffuse cerebral oedema, and meningeal inflammation was present in 12% of cases. The most used imaging test for both diagnosis and follow-up was magnetic resonance.

Fever was the most frequent sign (96%), followed by altered level of consciousness, including coma (57.7%); and seizures (38.5%). Signs of meningeal irritation were observed in 19.2% of the patients and vomiting in 11.5%. Among patients able to report symptoms (not premature infants), headache was a frequent symptom (40%) and visual disturbances (photophobia and blurred vision) were reported in 7.6% of cases.

In most cases (57.7%) B. cereus was identified by blood cultures. Direct culture of a nervous tissue sample (both in biopsy and autopsy) provided the diagnosis in 48.5% of the patients. Lumbar puncture was performed in less than half of the cases (42.3%), as it was considered an unsafe test due to underlying haematological alterations and the mass effect of the brain lesions. B. cereus was detected in the cerebrospinal fluid in 54.5% of the patients in whom lumbar puncture was performed.

CNS infections by B. cereus are a serious clinical condition, with an overall mortality of 57.7% in our series. Between groups, the differences in mortality were statistically significant, with lower mortality in the group of infections due to CNS interventions (0%), followed by the group of neutropenic patients (58.82%) and premature infants (85.71%). Vancomycin was the most widely used antibiotic (53.8% of the cases), however it did not show association with survival. Of patients who received vancomycin, 42.9% survived and of those who did not receive it, 41.7% survived (p = 0.95). Depending on the antibiogram, other antibiotics were used such as carbapenems (26.9%), aminoglycosides (23.1%) and cephalosporins (19.2%). None of these antibiotics showed a survival improvement except for carbapenems. We have found statistically significant differences (p = 0.024) between the survival of patients who were treated with carbapenems (75%) and those who did not receive them (27.8%). Meropenem was the most used carbapenem (75% of them) and demonstrated a statistically significant improvement in survival (p = 0.02). 83.3% of those who received meropenem survived and only 30% of those who did not. Only two patients (one adult and one premature) required surgery to drain the abscesses.
 

Discussion


Patients with CNS infections due to B. cereus can be classified into three well-defined profiles: preterm infants, neutropenic patients, and people with a history of CNS intervention. Most often, B. cereus produces multiple abscesses, reflecting a hematogenous spread of the bacteria. However, it can also lead to meningitis and encephalitis. Both in the imaging tests reviewed and in the pathological studies described so far [4,14], necrosis of the brain parenchyma is evident. Since B. cereus frequently affects neutropenic patients, it is likely that inflammatory response does not play a major role in pathogenesis. B. cereus secretes various toxins such as sphingomyelinase, phosphatidyl inositol phospholipase C, haemolysin II or pore-forming cytotoxins which have been reported as the main factors in tissue necrosis [23,24].

B. cereus has three main pathways into the body. On the one hand, anatomopathological studies demonstrate the presence of B. cereus in the digestive system of patients with CNS involvement [22]. Given the high co-existence of haematological malignancies, some authors have suggested that mucosal breaches caused by chemotherapy drugs such as cytarabine may be the point of entry into the bloodstream [4,25]. On the other hand, B. cereus produces biofilms that adhere easily to the surfaces of invasive devices such as intravenous lines or ventriculoperitoneal shunts [2]. From these surfaces, bacteria can be released into the bloodstream and spread to distant organs. The presence of biofilms is the reason why antibiotic treatment should be prolonged and invasive devices replaced. Finally, in patients with a history of CNS intervention, a direct invasion of the pathogen occurs.

Our patient suffered from acute lymphoblastic leukaemia and most of the cases reviewed had an underlying haematological malignancy. As we have argued, these diseases and related treatments meet most of requirements for B. cereus invasion into the CNS. Therefore, these patients constitute a high-risk group and early diagnostic suspicion of CNS infection due to B. cereus should be established in the presence of fever and neurological symptoms. In the case we report, the child had headache but, remarkably, he did not develop fever despite showing signs of shock. Analgesics with antipyretic function may be an explanation, but since he only received them if needed for pain, this possibility seems unlikely. We hypothesize that prolonged immunosuppression is the most plausible cause of absence of fever.

In our case, the blood cultures were negative, probably due to antibiotic treatment he was receiving prophylactically. We performed lumbar puncture because the abscess of our patient was small and had little associated oedema, so we considered it safe to carry it out after administration of a platelet pool. The definitive diagnosis was made through the identification of B. cereus in the cerebrospinal fluid. Since the lumbar puncture was non-traumatic, haematogenous contamination seems unlikely. Considering the profitability of the individual tests, whenever possible, both blood cultures and lumbar puncture should be performed.

B. cereus produces beta-lactamases and is resistant to penicillins and cephalosporins, therefore vancomycin is recommended as empirical treatment once this bacterium has been identified [26]. Other antibiotics such as aminoglycosides, clindamycin, or erythromycin may also be effective [14]. Interestingly, despite the small sample size, we found statistically significant differences between the survival of patients who received carbapenems and those who did not. This may be due to an adequate profile of carbapenems against B. cereus. They are bactericidal antibiotics active against gram-positive bacteria as well as against anaerobic species. Moreover, both imipenem and meropenem cross the blood-brain barrier and meropenem, apart from having demonstrated an improvement in survival in our series, has few adverse effects on the CNS [27,28]. Therefore, it could be a good option to empirically use in both, acute meningitis, and brain abscesses until antibiogram results are available.
 

Conclusions


CNS infections due to B. cereus are a heterogeneous group of entities with high overall mortality. Early suspicion in at-risk patients and adequate antibiotic treatment are essential to improve the prognosis.

 

References


 1. Jiménez G, Urdiain M, Cifuentes A, López-López A, Blanch AR, Tamames J, et al. Description of Bacillus toyonensis sp. nov., a novel species of the Bacillus cereus group, and pairwise genome comparisons of the species of the group by means of ANI calculations. Syst Appl Microbiol 2013; 36: 383-91.

 2. Sankararaman S, Velayuthan S. Bacillus cereus. Pediatr Rev 2013; 34: 196-7.

 3. De Almeida SM, Teive HA, Brandi I, Nabhan SK, Werneck LC, Bittencourt M, et al. Fatal Bacillus cereus meningitis without inflammatory reaction in cerebral spinal fluid after bone marrow transplantation. Transplantation 2003; 76: 1533-4.

 4. Brouland JP, Sala N, Tusgul S, Rebechini C, Kovari E. Bacillus cereus bacteremia with central nervous system involvement: a neuropathological study. Clin Neuropathol 2018; 37: 22-7.

 5. Chu WP, Que TL, Lee WK, Wong SN. Meningoencephalitis caused by Bacillus cereus in a neonate. Hong Kong Med J 2001; 7: 89-92.

 6. Dabscheck G, Silverman L, Ullrich NJ. Bacillus cereus cerebral abscess during induction chemotherapy for childhood acute leukemia. J Pediatr Hematol Oncol 2015; 37: 568-9.

 7. Drazin D, Lehman D, Danielpour M. Successful surgical drainage and aggressive medical therapy in a preterm neonate with Bacillus cereus meningitis. Pediatr Neurosurg 2010; 46: 466-71.

 8. Hansford JR, Phillips M, Cole C, Francis J, Blyth CC, Gottardo NG. Bacillus cereus bacteremia and multiple brain abscesses during acute lymphoblastic leukemia induction therapy. J Pediatr Hematol Oncol 2014; 36: e197-201.

 9. Ichikawa K, Gakumazawa M, Inaba A, Shiga K, Takeshita S, Mori M, et al. Acute encephalopathy of Bacillus cereus mimicking Reye syndrome. Brain Dev 2010; 32: 688-90.

 10. Koizumi Y, Okuno T, Minamiguchi H, Hodohara K, Mikamo H, Andoh A. Survival of a case of Bacillus cereus meningitis with brain abscess presenting as immune reconstitution syndrome after febrile neutropenia – a case report and literature review. BMC Infect Dis 2020; 20: 15.

 11. Kuwabara H, Kawano T, Tanaka M, Kobayashi S, Okabe G, Maruta A, et al. Cord blood transplantation after successful treatment of brain abscess caused by Bacillus cereus in a patient with acute myeloid leukemia. Rinsho Ketsueki 2006; 47: 1463-8.

 12. Lequin MH, Vermeulen JR, van Elburg RM, Barkhof F, Kornelisse RF, Swarte R, et al. Bacillus cereus meningoencephalitis in preterm infants: neuroimaging characteristics. Am J Neuroradiol 2005; 26: 2137-43.

 13. Manickam N, Knorr A, Muldrew KL. Neonatal meningoencephalitis caused by Bacillus cereus. Pediatr Infect Dis J 2008; 27: 843-6.

 14. Marley EF, Saini NK, Venkatraman C, Orenstein JM. Fatal Bacillus cereus meningoencephalitis in an adult with acute myelogenous leukemia. South Med J 1995; 88: 969-72.

 15. Melmed K, Kavi T. Teaching neuroimages: diffuse cerebral vasospasm and multiple intracranial abscesses from Bacillus cereus. Neurology 2016; 87: e97-8.

 16. Mori T, Tokuhira M, Takae Y, Mori S, Suzuki H, Abe T, et al. Successful non-surgical treatment of brain abscess and necrotizing fasciitis caused by Bacillus cereus. Intern Med 2002; 41: 671-3.

 17. Motoi N, Ishida T, Nakano I, Akiyama N, Mitani K, Hirai H, et al. Necrotizing Bacillus cereus infection of the meninges without inflammatory reaction in a patient with acute myelogenous leukemia: a case report. Acta Neuropathol 1997; 93: 301-5.

 18. Psiachou-Leonard E, Sidi V, Tsivitanidou M, Gompakis N, Koliouskas D, Roilides E. Brain abscesses resulting from Bacillus cereus and an Aspergillus-like mold. J Pediatr Hematol Oncol 2002; 24: 569-71.

 19. Saigal K, Gautam V, Singh G, Ray P. Bacillus cereus causing intratumoral brain abscess. Indian J Pathol Microbiol 2016; 59: 554-6.

 20. Sakai C, Iuchi T, Ishii A, Kumagai K, Takagi T. Bacillus cereus brain abscesses occurring in a severely neutropenic patient: successful treatment with antimicrobial agents, granulocyte colony-stimulating factor and surgical drainage. Intern Med 2001; 40: 654-7.

 21. Stevens MP, Elam K, Bearman G. Meningitis due to Bacillus cereus: a case report and review of the literature. Can J Infect Dis Med Microbiol 2012; 23: e16-9.

 22. Vodopivec I, Rinehart EM, Griffin GK, Johncilla ME, Pecora N, Yokoe DS, et al. A cluster of CNS infections due to B. cereus in the setting of acute myeloid leukemia: neuropathology in 5 patients. J Neuropathol Exp Neurol 2015; 74: 1000-11.

 23. Guillemet E, Cadot C, Tran SL, Guinebretière MH, Lereclus D, Ramarao N. The InhA metalloproteases of Bacillus cereus contribute concomitantly to virulence. J Bacteriol 2010; 192: 286-94.

 24. Gwarsha K, Rumsby MG, Little C. Action of phospholipase C (Bacillus cereus) on isolated myelin sheath preparations. Neurochem Int 1984; 6: 199-206.

 25. Stentoft J. The toxicity of cytarabine. Drug Saf 1990; 5: 7-27.

 26. Luna VA, King DS, Gulledge J, Cannons AC, Amuso PT, Cattani J. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre automated microbroth dilution and Etest agar gradient diffusion methods. J Antimicrob Chemother 2007; 60: 555-67.

 27. Breilh D, Texier-Maugein J, Allaouchiche B, Saux MC, Boselli E. Carbapenems. J Chemother 2013; 25: 1-17.

 28. Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs 2013; 15: 93-117.

 

Infección del sistema nervioso central por Bacillus cereus: descripción de un caso y revisión de la bibliografía


Introducción. Bacillus cereus es un patógeno ubicuo que, habitualmente, produce síntomas gastrointestinales autolimitados. Sin embargo, en pacientes susceptibles, puede dar lugar a infecciones del sistema nervioso central potencialmente mortales.

Desarrollo. Presentamos el caso de un varón de 10 años en tratamiento quimioterápico por leucemia linfoblástica aguda. Durante el período de inducción desarrolló un absceso cerebral por B. cereus que fue diagnosticado mediante pruebas de imagen y detección directa en el líquido cefalorraquídeo. Su evolución fue favorable con tratamiento antibiótico.

Conclusiones. Hasta ahora se han descrito en la bibliografía otros 26 casos de infección del sistema nervioso central por B. cereus, que, además de ser infrecuentes, suponen un reto diagnóstico. Sin embargo, en los recién nacidos prematuros, en pacientes con neoplasias hematológicas o con antecedentes de cirugía del sistema nervioso central, debe establecerse una sospecha temprana para iniciar un tratamiento antibiótico adecuado que mejore el pronóstico.

Palabras clave. Absceso. Bacillus cereus. Carbapenémicos. Cuidados críticos. Neoplasia hematológica. Sistema nervioso central.
 

 

© 2022 Revista de Neurología

Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.


Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
Datos básicos
He leído y acepto la política de privacidad y el aviso legal
Seleccione la casilla si desea recibir el número quincenal de Revista de Neurología por correo electrónico. De forma quincenal se le mandará un correo con los títulos de los artículos publicados en Revista de Neurología.
Seleccione la casilla si desea recibir el boletín semanal de Revista de Neurología por correo electrónico. El boletín semanal es una selección de las noticias publicadas diariamente en Revista de Neurología.
Seleccione la casilla si desea recibir información general de neurologia.com (Entrevistas, nuevos cursos de formación, eventos, etc.)
Datos complementarios

Se os solicita los datos de redes para dar repercusión por estos medios a las publicaciones en las que usted participe.



Estimado usuario de Revista de Neurología,

Debido a la reciente fusión por absorción de VIGUERA EDITORES, S.L.U., la entidad gestora de las publicaciones de Viguera Editores, entre ellas, Revista de Neurología, por EVIDENZE HEALTH ESPAÑA, S.L.U., una de las sociedades también pertenecientes al Grupo Evidenze, y con la finalidad de que Usted pueda seguir disfrutando de los contenidos y distintos boletines a los que está suscrito en la página web de neurologia.com, es imprescindible que revise la nueva política de privacidad y nos confirme la autorización de la cesión de sus datos.

Lamentamos informarle que en caso de no disponer de su consentimiento, a partir del día 28 de octubre no podrá acceder a la web de neurologia.com

Para dar su consentimiento a seguir recibiendo la revista y los boletines de neurologia.com vía correo electrónico y confirmar la aceptación de la nueva política de privacidad, así como la cesión de sus datos a Evidenze Health España S.L.U., el resto de las entidades del Grupo Evidenze y sus partners y colaboradores comerciales, incluyendo la posibilidad de llevar a cabo transferencias internacionales a colaboradores extranjeros, pulse en el siguiente enlace:

ACEPTAR

Cancelar

Atentamente

El equipo de Revista de Neurología